FLGT

#2871
Fulgent Genetics, Inc. - Common Stock
19.6 1 USD
+0.01%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
19.61
19.61
Intervallo Annuale
13.46
31.04
Variazione giornaliera
+0.71%
Variazione Mensile
+18.06%
Variazione di 6 mesi
+31.79%
Variazione Annuale
-17.01%
Chiusura Precedente
19.9 5
Open
19.6 1
Minimo
19.6 1
Massimo
19.6 1
Volume
40
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
Fulgent Genetics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Fulgent Genetics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Fulgent Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Fulgent Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Fulgent Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Fulgent Genetics, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Fulgent Genetics, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Fulgent Genetics, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Fulgent Genetics, Inc. current report, Q1 FY2026
8-K

2025

Annual report, FY2025
Fulgent Genetics, Inc. annual report, FY2025
10-K

Fulgent Genetics, Inc. current report, Q2 FY2021

Full document

Fulgent Genetics, Inc. Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K, dated May 20, 2021, details the results of the 2021 Annual Meeting of Stockholders for Fulgent Genetics, Inc. The meeting was held on May 20, 2021, at the Company's offices in El Monte, California. As of the record date of March 26, 2021, there were 28,989,270 shares of common stock issued and outstanding eligible to vote.

Key Financial Metrics

This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance matters and voting results.

Material Changes and Voting Results

A quorum of 20,169,388 shares, representing approximately 70% of eligible shares, was present. The following actions were taken:

  • Proposal 1: Election of Directors
    • Ming Hsieh: 13,111,071 votes For; 140,707 votes Withheld.
    • John Bolger: 13,091,491 votes For; 160,287 votes Withheld.
    • Yun Yen, M.D., Ph.D., F.A.C.P.: 12,798,371 votes For; 453,407 votes Withheld.
    • Linda Marsh: 13,090,514 votes For; 161,264 votes Withheld.
    • All nominees were elected to serve until the 2022 Annual Meeting.
  • Proposal 2: Ratification of Auditors
    • Deloitte & Touche LLP was ratified as the Independent Registered Public Accounting Firm for the year ending December 31, 2021.
    • Votes For: 20,059,361; Votes Against: 73,241; Votes Abstained: 36,786.

Guidance, Outlook, and Risks

The filing does not provide management commentary, financial guidance, outlook, or specific risk factors. It references the definitive proxy statement filed on April 1, 2021, for detailed descriptions of the matters voted upon.

Key Facts for Investor Verification

  • Verify the final composition of the Board of Directors following the election of Ming Hsieh, John Bolger, Yun Yen, and Linda Marsh.
  • Confirm the engagement of Deloitte & Touche LLP as the independent auditor for the fiscal year ending December 31, 2021.
  • Review the definitive proxy statement filed on April 1, 2021, for comprehensive details on director biographies and audit committee matters.
  • Note that approximately 6.9 million shares were recorded as broker non-votes for the director elections.

Notizie